You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
Todos said it believes that gaining access to a medical grade ventilator will bring further attention to its coronavirus tests.
The PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in various respiratory specimens including oropharyngeal swabs.
The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.
PreCheck Health has an initial order of 30,000 tests and will register the product in Ecuador. The two firms have a similar distribution agreement covering Russia.
The company anticipates launching an in vitro diagnostic version of the 10-gene ThyroidPrint assay in South America and Europe after receiving regulatory clearance by Q2 2021.
The tests performed well, with researchers suggested they could be used for diagnosis in the future, rather than just screening.
Newly discovered biomarkers of preterm birth risk — D-lactic acid and TIMP-1 — may lead to a simple ELISA test at the point of care, its developers said.
Isothermal molecular assays to diagnose a parasitic infection that afflicts approximately 300 million people are moving closer to commercialization.